Answers are grounded in this paper and cite their sources.
-CAR T cells without upregulating exhaustion markers (PD-1/LAG3). These findings suggest that in the management of treatment-resistant pediatric solid tumors, utilizing chidamide during the manufacturing of CRISPR-engineered CAR T cells may enhance their persistence while retaining a naive phenotype.
No takes yet. Share an insight, caveat, or question.
Cappabianca et al. (2026) studied this question.